Your browser doesn't support javascript.
Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease.
Qiao, Huarui; Li, Lingyun; Wang, Lu; Yu, Haijun; Hu, Fangzheng; Zhou, Xin; Yang, Hongzhao; Xu, Jianfeng; Meng, Xiangjing; Geng, Yong; Dai, Yuanyuan.
  • Qiao H; Department of Biopharmaceutics, College of Food Science and Technology, Shanghai Ocean University, Shanghai, 201306, China.
  • Li L; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Wang L; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Yu H; State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Hu F; Department of Biopharmaceutics, College of Food Science and Technology, Shanghai Ocean University, Shanghai, 201306, China.
  • Zhou X; Department of Biopharmaceutics, College of Food Science and Technology, Shanghai Ocean University, Shanghai, 201306, China.
  • Yang H; Department of Biopharmaceutics, College of Food Science and Technology, Shanghai Ocean University, Shanghai, 201306, China.
  • Xu J; Department of Biopharmaceutics, College of Food Science and Technology, Shanghai Ocean University, Shanghai, 201306, China. Electronic address: jfxu@shou.edu.cn.
  • Meng X; Shandong Provincial Key Laboratory of Biopharmaceuticals, Shandong Academy of Pharmaceutical Sciences, Jinan, 250101, China. Electronic address: fredamxj@163.com.
  • Geng Y; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, Beijing, 100049, China. Electronic address: gengyong@simm.ac.cn.
  • Dai Y; Department of Pharmacy, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; National Cancer Center, National Clinical Research Center for Cancer/Hebei Cancer Hospital, Chin
Protein Expr Purif ; 207: 106267, 2023 07.
Article in English | MEDLINE | ID: covidwho-2302124
ABSTRACT
Coronavirus Papain-like protease (PLpro) mediates the cleavage of viral polyproteins and assists the virus escaping from innate immune response. Thus, PLpro is an attractive target for the development of broad-spectrum drugs as it has a conserved structure across different coronaviruses. In this study, we purified SARS-CoV-2 PLpro as an immune antigen, constructed a nanobody phage display library, and identified a set of nanobodies with high affinity for SARS-CoV-2. In addition, enzyme activity experiments demonstrated that two nanobodies had a significant inhibitory effect on the PLpro. These nanobodies should therefore be investigated as candidates for the treatment of coronaviruses.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Single-Domain Antibodies / COVID-19 Limits: Humans Language: English Journal: Protein Expr Purif Journal subject: Molecular Biology Year: 2023 Document Type: Article Affiliation country: J.pep.2023.106267

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Single-Domain Antibodies / COVID-19 Limits: Humans Language: English Journal: Protein Expr Purif Journal subject: Molecular Biology Year: 2023 Document Type: Article Affiliation country: J.pep.2023.106267